TACLONEX Side Effects

7019276-X | Contusion, Cushingoid, Depression, Fatigue, Intervertebral Disc Protrusion, Lipohypertrophy, Pollakiuria, Sleep Apnoea Syndrome, Weight Increased
on Sep 15, 2010 Female patient from UNITED STATES , 40 years of age, weighting 215.2 lb, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: contusion, cushingoid, depression (What is depression?), fatigue, intervertebral disc protrusion, lipohypertrophy, pollakiuria, sleep apnoea syndrome, weight increased. Taclonex dosage: Unk (every Day) Topical. During the same period patient was treated with ARMODAFINIL (ARMODAFINIL) (View Armodafinil (armodafinil) Review and Armodafinil (armodafinil) Label ), LIPSIN (FENOFIBRATE) (View Lipsin (fenofibrate) Review and Lipsin (fenofibrate) Label ), EFFEXOR (View Effexor Review and Effexor Label ). Patient was hospitalized.

6971034-8 | Anaphylactic Reaction
Patient was taking Taclonex (View Usage). Patient had the following side effects: anaphylactic reaction on Aug 25, 2010 from CANADA Additional patient health information: Male patient , 68 years of age, weighting 203.0 lb, . Taclonex dosage: Topical. During the same period patient was treated with DILANTIN (PHENYTOIN) (100 MILLIGRAM) (View Dilantin (phenytoin) (100 Milligram) Review and Dilantin (phenytoin) (100 Milligram) Label ), PERINDOPRIL ERBUMINE (View Perindopril Erbumine Review and Perindopril Erbumine Label ), TECTA (PANTOPRAZOLE SODIUM) (View Tecta (pantoprazole Sodium) Review and Tecta (pantoprazole Sodium) Label ).

6963031-3 | Angle Closure Glaucoma, Off Label Use
Adverse event was reported on Aug 18, 2010 by a Male patient taking Taclonex (View Usage) (Dosage: (2 In 1d)) was diagnosed with rash (What is rash?) and. Location: UNITED KINGDOM , 65 years of age, After Taclonex was administered, patient had the following side effects: angle closure glaucoma, off label use.

6955977-7 | Erythrodermic Psoriasis, Hyperkeratosis, Oedema Peripheral, Off Label Use, Pruritus, Skin Exfoliation
on Aug 12, 2010 Male patient from FRANCE , 76 years of age, weighting 189.6 lb, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: erythrodermic psoriasis, hyperkeratosis, oedema peripheral, off label use, pruritus, skin exfoliation. Taclonex dosage: Topical. During the same period patient was treated with DAIVONEX (CALCIPOTRIOL) (View Daivonex (calcipotriol) Review and Daivonex (calcipotriol) Label ), DAIVOBET (BETHAMETHASONE DIPROPIONATE, CALCIPOTRIOL) (View Daivobet (bethamethasone Dipropionate, Calcipotriol) Review and Daivobet (bethamethasone Dipropionate, Calcipotriol) Label ), BETAMETHASONE VALERATE (View Betamethasone Valerate Review and Betamethasone Valerate Label ), SORIATANE (View Soriatane Review and Soriatane Label ). Patient was hospitalized.


6929704-3 | Dyspnoea
on Aug 02, 2010 Female patient from NETHERLANDS , 42 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient had the following side effects: dyspnoea. Taclonex dosage: 1, Topical. Patient was hospitalized.

6917245-9 | Angle Closure Glaucoma, Blister, Off Label Use
Patient was taking Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: angle closure glaucoma, blister, off label use on Jul 26, 2010 from UNITED STATES Additional patient health information: Male patient , 65 years of age, was diagnosed with rash (What is rash?) and. Taclonex dosage: 2 In 1 D.

6730830-2 | Ectropion, Erythrodermic Psoriasis, Hyperkeratosis, Oedema Peripheral, Off Label Use, Pruritus, Skin Exfoliation, Weight Decreased
Adverse event was reported on May 03, 2010 by a Male patient taking Taclonex (View Usage) (Dosage: Topical) was diagnosed with psoriasis and. Location: FRANCE , 76 years of age, weighting 189.6 lb, Patient experienced the following unwanted or unexpected effects: ectropion, erythrodermic psoriasis, hyperkeratosis, oedema peripheral, off label use, pruritus, skin exfoliation, weight decreased. During the same period patient was treated with DAIVONEX (CALCIPOTRIOL) (View Daivonex (calcipotriol) Review and Daivonex (calcipotriol) Label ), DAIVOBET (BETAMETHASONE DIPROPIONATE, CALCIPOTRIOL) (View Daivobet (betamethasone Dipropionate, Calcipotriol) Review and Daivobet (betamethasone Dipropionate, Calcipotriol) Label ), BETAMETHASONE VALERATE (View Betamethasone Valerate Review and Betamethasone Valerate Label ), SORIATANE (View Soriatane Review and Soriatane Label ). Patient was hospitalized.

6723289-2 | Condition Aggravated, Dermatitis Exfoliative, Off Label Use, Overdose, Psoriasis
on Dec 09, 2009 Female patient from FRANCE , 49 years of age, weighting 213.8 lb, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient had the following side effects: condition aggravated, dermatitis exfoliative, off label use, overdose, psoriasis. Taclonex dosage: 0.5 To 1.0 Tube. During the same period patient was treated with RAPTIVA (66 Mg Weekly, Subcutaneous) (View Raptiva Review and Raptiva Label ). Patient was hospitalized.

6720613-1 | Blood Pressure Increased, Decreased Appetite, Headache, Heart Rate Increased, Insomnia, Off Label Use
on Dec 09, 2009 Female patient from UNITED STATES , 43 years of age, weighting 128.0 lb, was diagnosed with eczema (What is eczema?) and was treated with Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: blood pressure increased, decreased appetite, headache (What is headache?), heart rate increased, insomnia, off label use. Taclonex dosage: 3 Application (3 In 1 D), Topical. During the same period patient was treated with DIOVAN (View Diovan Review and Diovan Label ).

6720053-5 | Cataract, Off Label Use, Vision Blurred, Visual Acuity Reduced
Patient was taking Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: cataract (What is cataract?), off label use, vision blurred, visual acuity reduced on Nov 12, 2007 from DENMARK Additional patient health information: Female patient , 50 years of age, weighting 191.8 lb, was diagnosed with psoriasis and. Taclonex dosage: Infrequent Use, 1-2 Times A Week, Cutaneous. During the same period patient was treated with DUACT (PSEUDOEPHEDRINE HYDROCHLORIDE, ACRIVASTINE) CAPSULES (View Duact (pseudoephedrine Hydrochloride, Acrivastine) Capsules Review and Duact (pseudoephedrine Hydrochloride, Acrivastine) Capsules Label ). Patient was hospitalized.

6719138-9 | Neuropathy Peripheral, Off Label Use
Adverse event was reported on Dec 09, 2009 by a Female patient taking Taclonex (View Usage) (Dosage: 1 In 1 D, Topical) was diagnosed with psoriasis and. Location: UNITED STATES , 79 years of age, Patient had the following side effects: neuropathy peripheral, off label use.

6692834-8 | Abortion Induced, Sex Chromosome Abnormality
on Apr 06, 2010 Female patient from FRANCE , 30 years of age, was treated with Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: abortion induced, sex chromosome abnormality. Taclonex dosage: Topical, During Several Weeks.

6613473-0 | Chills, Pustular Psoriasis, Pyrexia, Xerosis
on Feb 17, 2010 Female patient from DENMARK , 76 years of age, was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: chills, pustular psoriasis, pyrexia, xerosis. Taclonex dosage: Topical. During the same period patient was treated with LAMISIL (Per Oral) (View Lamisil Review and Lamisil Label ), DERMOVAL (CLOBETASOL PROPIONATE) (View Dermoval (clobetasol Propionate) Review and Dermoval (clobetasol Propionate) Label ). Patient was hospitalized.

6613462-6 | Abasia, Application Site Burn, Off Label Use
Patient was taking Taclonex (View Usage). Patient had the following side effects: abasia, application site burn, off label use on Feb 17, 2010 from FRANCE Additional patient health information: Male patient , 80 years of age, was diagnosed with hyperkeratosis and. Taclonex dosage: Topical.

6599983-3 | Abortion Spontaneous, Adrenal Insufficiency, Anxiety, Cushing's Syndrome, Dermatitis Exfoliative, Dizziness, Erythrodermic Psoriasis, Fatigue, Headache
Adverse event was reported on Jan 28, 2010 by a Female patient taking Taclonex (View Usage) (Dosage: }60g Per Day, Topical) was diagnosed with psoriasis and. Location: FRANCE , 25 years of age, After Taclonex was administered, patient had the following side effects: abortion spontaneous, adrenal insufficiency, anxiety (What is anxiety?), cushing's syndrome, dermatitis exfoliative, dizziness (What is dizziness?), erythrodermic psoriasis, fatigue, headache (What is headache?). During the same period patient was treated with RHEUMATREX (View Rheumatrex Review and Rheumatrex Label ), ENBREL (View Enbrel Review and Enbrel Label ), ACITRETIN (View Acitretin Review and Acitretin Label ), LEFLUNOMIDE (View Leflunomide Review and Leflunomide Label ), TENORMIN (View Tenormin Review and Tenormin Label ), IRBESARTAN (View Irbesartan Review and Irbesartan Label ), DAFLON (DIOSMIN) (View Daflon (diosmin) Review and Daflon (diosmin) Label ). Patient was hospitalized.

6580046-8 | Adrenal Insufficiency, Arrhythmia, Conduction Disorder, Cushing's Syndrome, Depression, Dizziness, Erythrodermic Psoriasis, Headache, Hyperkeratosis
on Jan 22, 2010 Female patient from FRANCE , 25 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: adrenal insufficiency, arrhythmia (What is arrhythmia?), conduction disorder, cushing's syndrome, depression (What is depression?), dizziness (What is dizziness?), erythrodermic psoriasis, headache (What is headache?), hyperkeratosis. Taclonex dosage: 60g Per Day, Topical. During the same period patient was treated with NOVATREX (METHYOTREXATE) (View Novatrex (methyotrexate) Review and Novatrex (methyotrexate) Label ), ENBREL (View Enbrel Review and Enbrel Label ), ACITRETIN (View Acitretin Review and Acitretin Label ), LEFLUNOMIDE (LEFL7UNOMIDE) (View Leflunomide (lefl7unomide) Review and Leflunomide (lefl7unomide) Label ), TENORMIN (View Tenormin Review and Tenormin Label ), IRBESARTAN (View Irbesartan Review and Irbesartan Label ), DAFLON (DIOSMIN) (View Daflon (diosmin) Review and Daflon (diosmin) Label ). Patient was hospitalized.

6536911-0 | Alopecia, Auricular Swelling, Dyspnoea, Feeling Of Body Temperature Change, Headache, Lymphadenopathy, Pain Of Skin
on Dec 21, 2009 Female patient from DENMARK , 47 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient had the following side effects: alopecia, auricular swelling, dyspnoea, feeling of body temperature change, headache (What is headache?), lymphadenopathy, pain of skin. Taclonex dosage: Topical.

6496295-3 | Erythrodermic Psoriasis, Off Label Use, Pyrexia
Patient was taking Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: erythrodermic psoriasis, off label use, pyrexia on Nov 23, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 62 years of age, was diagnosed with psoriasis and. Taclonex dosage: Topical. During the same period patient was treated with PREDNISOLONE ACETATE (View Prednisolone Acetate Review and Prednisolone Acetate Label ), CHINESE HERBAL LOTION (View Chinese Herbal Lotion Review and Chinese Herbal Lotion Label ), FEXOFENADINE HCL (View Fexofenadine Hcl Review and Fexofenadine Hcl Label ).

6443943-X | Erysipelas
Adverse event was reported on Oct 30, 2009 by a Male patient taking Taclonex (View Usage) (Dosage: Qd, Topical) was diagnosed with psoriasis and. Location: DENMARK , 55 years of age, Patient experienced the following unwanted or unexpected effects: erysipelas. During the same period patient was treated with ADALIMUMAB (ADALIMUMAB) 80MG (View Adalimumab (adalimumab) 80mg Review and Adalimumab (adalimumab) 80mg Label ), DIPYRIDAMOLE (View Dipyridamole Review and Dipyridamole Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), VASERETIC (View Vaseretic Review and Vaseretic Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ). Patient was hospitalized.

6443909-X | Malignant Melanoma
on Oct 30, 2009 Female patient from DENMARK , 56 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient had the following side effects: malignant melanoma. Taclonex dosage: Topical. During the same period patient was treated with HUMIRA (40 Mg, Subcutaneous, 20 Mg, Oral) (View Humira Review and Humira Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), RIFAMPICIN (View Rifampicin Review and Rifampicin Label ).

6443888-5 | Chills, Erysipelas, Hypotension, Pustular Psoriasis
on Oct 30, 2009 Female patient from AUSTRIA , 44 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: chills, erysipelas, hypotension, pustular psoriasis. Taclonex dosage: Qd, Topical. During the same period patient was treated with ADALIMUMAB (ADALIMUMAB) (40 Mg Biw, Topical; 40 Mg Biw, Topical) (View Adalimumab (adalimumab) Review and Adalimumab (adalimumab) Label ), CLINDAMYCIN HCL (View Clindamycin Hcl Review and Clindamycin Hcl Label ), AMOXICILLIN (View Amoxicillin Review and Amoxicillin Label ). Patient was hospitalized.

6442353-9 | Erythrodermic Psoriasis, Off Label Use
Patient was taking Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: erythrodermic psoriasis, off label use on Oct 29, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 62 years of age, was diagnosed with psoriasis and. Taclonex dosage: Topical. During the same period patient was treated with PREDNISOLONE ACETATE (View Prednisolone Acetate Review and Prednisolone Acetate Label ), CHINESE HERBAL LOTION (View Chinese Herbal Lotion Review and Chinese Herbal Lotion Label ), FEXOFENADINE HCL (View Fexofenadine Hcl Review and Fexofenadine Hcl Label ).

6438134-2 | Abasia, Burning Sensation, Off Label Use
Adverse event was reported on Oct 28, 2009 by a Male patient taking Taclonex (View Usage) (Dosage: Topical) was diagnosed with hyperkeratosis and. Location: FRANCE , 80 years of age, Patient had the following side effects: abasia, burning sensation, off label use.

6414413-X | Acute Myeloid Leukaemia, Pancytopenia, Pneumonia, Pustular Psoriasis
on Oct 06, 2009 Female patient from IRELAND , 66 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: acute myeloid leukaemia, pancytopenia, pneumonia (What is pneumonia?), pustular psoriasis. Taclonex dosage: 60 G, In One Wek X Two Months. During the same period patient was treated with HYDROXYUREA (View Hydroxyurea Review and Hydroxyurea Label ), ACITRETIN (View Acitretin Review and Acitretin Label ).

6380288-0 | Acute Myeloid Leukaemia, Pancytopenia, Pneumonia, Pustular Psoriasis
on Sep 09, 2009 Female patient from IRELAND , 66 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, pancytopenia, pneumonia (What is pneumonia?), pustular psoriasis. Taclonex dosage: 60 G, In One Week X Two Months.

6283988-6 | Gastroenteritis, Respiratory Tract Infection, Upper Respiratory Tract Infection
Patient was taking Taclonex (View Usage). Patient had the following side effects: gastroenteritis (What is gastroenteritis?), respiratory tract infection, upper respiratory tract infection on Jul 09, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 42 years of age, was diagnosed with psoriasis and. Taclonex dosage: Topical.

6260458-2 | Erythrodermic Psoriasis, Overdose
Adverse event was reported on Jun 18, 2009 by a Male patient taking Taclonex (View Usage) (Dosage: Topical) . Location: UNITED KINGDOM , 53 years of age, After Taclonex was administered, patient had the following side effects: erythrodermic psoriasis, overdose. Patient was hospitalized.

6260276-5 | Erythrodermic Psoriasis, Toxic Skin Eruption
on Jun 22, 2009 Male patient from FRANCE , 47 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: erythrodermic psoriasis, toxic skin eruption. Taclonex dosage: Topical. During the same period patient was treated with BUSPIRONE HCL (View Buspirone Hcl Review and Buspirone Hcl Label ). Patient was hospitalized.

6249955-3 | Blister, Retinal Disorder, Visual Impairment
on Jun 12, 2009 Female patient from UNITED STATES , 50 years of age, was treated with Taclonex (View Usage). Patient had the following side effects: blister, retinal disorder (What is retinal disorder?), visual impairment. Taclonex dosage: Topical.

6236185-4 | Condition Aggravated, Precancerous Skin Lesion, Psoriasis
Patient was taking Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: condition aggravated, precancerous skin lesion, psoriasis on Jun 02, 2009 from UNITED STATES Additional patient health information: Male patient , 70 years of age, weighting 200.0 lb, was diagnosed with psoriasis and. Taclonex dosage: Topical. During the same period patient was treated with PRAVACHOL (View Pravachol Review and Pravachol Label ), HYTRIN (View Hytrin Review and Hytrin Label ), VALIUM (View Valium Review and Valium Label ).

6219971-6 | Chills, Pustular Psoriasis, Pyrexia
Adverse event was reported on May 20, 2009 by a Female patient taking Taclonex (View Usage) (Dosage: Unk Topical) . Location: FRANCE , 76 years of age, Patient experienced the following unwanted or unexpected effects: chills, pustular psoriasis, pyrexia. During the same period patient was treated with LAMISIL (Unk Oral) (View Lamisil Review and Lamisil Label ), DERMOVAL /00337102/ (CLOBETASOL PROPIONATE) (View Dermoval /00337102/ (clobetasol Propionate) Review and Dermoval /00337102/ (clobetasol Propionate) Label ). Patient was hospitalized.

6212327-1 | Acute Myeloid Leukaemia, Pneumonia, Pustular Psoriasis
on May 13, 2009 Female patient from IRELAND , 66 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient had the following side effects: acute myeloid leukaemia, pneumonia (What is pneumonia?), pustular psoriasis. Taclonex dosage: 60 G, 1 Week.

6097141-2 | Pharyngeal Oedema
on Feb 09, 2009 Female patient from DENMARK , 47 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: pharyngeal oedema. Taclonex dosage: Topical. During the same period patient was treated with EPIPEN (View Epipen Review and Epipen Label ).

6087263-4 | Cardiac Failure Congestive
Patient was taking Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac failure congestive on Feb 10, 2009 from UNITED STATES Additional patient health information: Male patient , 61 years of age, was diagnosed with psoriasis and. Taclonex dosage: 100 Gm, Topical, Topical. During the same period patient was treated with ZETIA (View Zetia Review and Zetia Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ).

6075828-5 | Pharyngeal Oedema
Adverse event was reported on Jan 26, 2009 by a Female patient taking Taclonex (View Usage) (Dosage: Topical) . Location: UNITED KINGDOM , 46 years of age, Patient had the following side effects: pharyngeal oedema.

5947628-5 | Blood Triglycerides Increased, Mean Cell Haemoglobin Increased, Mean Cell Volume Abnormal, Platelet Count Decreased, Red Blood Cell Count Decreased
on Oct 29, 2008 Male patient from UNITED STATES , 67 years of age, weighting 209.9 lb, was diagnosed with psoriasis and was treated with Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: blood triglycerides increased, mean cell haemoglobin increased, mean cell volume abnormal, platelet count decreased, red blood cell count decreased. Taclonex dosage: Qd, Topical. During the same period patient was treated with OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ), MOISTUREL (SODIUM LAURETH SULFATE) (View Moisturel (sodium Laureth Sulfate) Review and Moisturel (sodium Laureth Sulfate) Label ), CLEANSER (View Cleanser Review and Cleanser Label ), LIGHT TREATMENT (View Light Treatment Review and Light Treatment Label ), B12 (CYANOCOBALAMIN TANNIN COMPLEX) (View B12 (cyanocobalamin-tannin Complex) Review and B12 (cyanocobalamin-tannin Complex) Label ), VITAMIN E /00110501/ (TOCOPHEROL) (View Vitamin E /00110501/ (tocopherol) Review and Vitamin E /00110501/ (tocopherol) Label ), CENTRUM /00554501/ (MINERALS NOS, VITAMINS NOS) (View Centrum /00554501/ (minerals Nos, Vitamins Nos) Review and Centrum /00554501/ (minerals Nos, Vitamins Nos) Label ).

5940838-2 | Erythema, Musculoskeletal Pain, Pain In Extremity, Paraesthesia, Skin Exfoliation, Thermal Burn
on Oct 17, 2008 Male patient from FRANCE , 48 years of age, weighting 176.4 lb, was diagnosed with psoriasis, hepatitis (What is hepatitis?) and was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: erythema, musculoskeletal pain, pain in extremity, paraesthesia, skin exfoliation, thermal burn. Taclonex dosage: Topical. During the same period patient was treated with DOVONEX (View Dovonex Review and Dovonex Label ), ENTECAVIR() TABLET, .50MG (0.5, Qd, Oral) (View Entecavir() Tablet, .50mg Review and Entecavir() Tablet, .50mg Label ), METHOTREXATE (0.075, Qd, Oral) (View Methotrexate Review and Methotrexate Label ), BARACLUDE (View Baraclude Review and Baraclude Label ). Patient was hospitalized.

5924504-5 | Erysipelas, Hypersensitivity, Pustular Psoriasis
Patient was taking Taclonex (View Usage). Patient had the following side effects: erysipelas, hypersensitivity, pustular psoriasis on Sep 29, 2008 from AUSTRIA Additional patient health information: Female patient , 44 years of age, was diagnosed with psoriasis and. Taclonex dosage: Qd, Topical. During the same period patient was treated with ADALIMUMAB(ADALIMUMAB) (40 Mg Biw, Topical; 40 Mg Biw, Topical) (View Adalimumab(adalimumab) Review and Adalimumab(adalimumab) Label ), CLINDAMYCIN HCL (View Clindamycin Hcl Review and Clindamycin Hcl Label ), AMOXICILLIN (View Amoxicillin Review and Amoxicillin Label ). Patient was hospitalized.

5917713-2 | Malignant Melanoma
Adverse event was reported on Sep 25, 2008 by a Female patient taking Taclonex (View Usage) (Dosage: 28571 Mg, Qd, Topical) was diagnosed with psoriasis and. Location: DENMARK , 56 years of age, After Taclonex was administered, patient had the following side effects: malignant melanoma. During the same period patient was treated with HUMIRA (See Image) (View Humira Review and Humira Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ACETYLSALICYLIC ACID SRT (View Acetylsalicylic Acid Srt Review and Acetylsalicylic Acid Srt Label ), RIFAMPICIN (View Rifampicin Review and Rifampicin Label ).

5877353-0 | Erysipelas
on Aug 26, 2008 Male patient from DENMARK , 55 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: erysipelas. Taclonex dosage: Qd, Topical. During the same period patient was treated with ADALIMUMAB(ADALIMUMAB) 80MG (80 Mg, Subcutaneous) (View Adalimumab(adalimumab) 80mg Review and Adalimumab(adalimumab) 80mg Label ), DIPYRIDAMOLE (View Dipyridamole Review and Dipyridamole Label ), ACETYLSALICYLIC ACID SRT (View Acetylsalicylic Acid Srt Review and Acetylsalicylic Acid Srt Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), VASERETIC (View Vaseretic Review and Vaseretic Label ), ISONIAZID (ISONIZID) (View Isoniazid (isonizid) Review and Isoniazid (isonizid) Label ). Patient was hospitalized.

5877312-8 | Erythrodermic Psoriasis
on Aug 25, 2008 Male patient from SPAIN , 48 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient had the following side effects: erythrodermic psoriasis. Taclonex dosage: 80 Mg, Topical. During the same period patient was treated with HUMIRA (Subcutaneous) (View Humira Review and Humira Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), EPROSARTAN MESILATE (EPROSARTAN MESILATE) (View Eprosartan Mesilate (eprosartan Mesilate) Review and Eprosartan Mesilate (eprosartan Mesilate) Label ). Patient was hospitalized.

5827174-X | Convulsion Neonatal, Growth Retardation, Hypercalcaemia, Infantile Apnoeic Attack, Neonatal Disorder, Premature Baby, Sepsis Neonatal
Patient was taking Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: convulsion neonatal, growth retardation, hypercalcaemia, infantile apnoeic attack, neonatal disorder, premature baby, sepsis neonatal on Jul 14, 2008 from UNITED KINGDOM Additional patient health information: Male patient , weighting 3.31 lb, was diagnosed with vitamin supplementation and. Taclonex dosage: Transplacental. During the same period patient was treated with ABIDEC (ASCORBIC ACID, ERGOCALCIFROL, NICOTINAMIDE, RETINOL, RIBOFLAVI (0.6 Ml, Oral) (View Abidec (ascorbic Acid, Ergocalcifrol, Nicotinamide, Retinol, Riboflavi Review and Abidec (ascorbic Acid, Ergocalcifrol, Nicotinamide, Retinol, Riboflavi Label ), SANDOZ (View Sandoz Review and Sandoz Label ), PHOSPHATE SANDOZ /00504001/ (POTASSIUM BICARBONATE, SODIUM BICARBONATE (View Phosphate-sandoz /00504001/ (potassium Bicarbonate, Sodium Bicarbonate Review and Phosphate-sandoz /00504001/ (potassium Bicarbonate, Sodium Bicarbonate Label ), CEFOTAXIME SODIUM (View Cefotaxime Sodium Review and Cefotaxime Sodium Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ), CODEINE SUL TAB (View Codeine Sul Tab Review and Codeine Sul Tab Label ), LABETALOL HCL (View Labetalol Hcl Review and Labetalol Hcl Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

5826986-6 | Dermatitis Exfoliative
Adverse event was reported on Jul 14, 2008 by a Male patient taking Taclonex (View Usage) (Dosage: Topical) . Location: FRANCE , 40 years of age, Patient experienced the following unwanted or unexpected effects: dermatitis exfoliative. During the same period patient was treated with HUMIRA (View Humira Review and Humira Label ). Patient was hospitalized.

5819211-3 | Growth Retardation, Hypercalcaemia, Infantile Apnoeic Attack, Neonatal Disorder, Premature Baby, Sepsis Neonatal
on Jul 01, 2008 Male patient from UNITED KINGDOM , weighting 3.31 lb, was diagnosed with vitamin supplementation and was treated with Taclonex (View Usage). Patient had the following side effects: growth retardation, hypercalcaemia, infantile apnoeic attack, neonatal disorder, premature baby, sepsis neonatal. Taclonex dosage: Transplacental. During the same period patient was treated with ABIDEC(ASCORBIC ACID, ERGOCALCIFEROL, NICOTINAMIDE, RETINOL, RIBOFLAVI (0.6 Ml, Oral) (View Abidec(ascorbic Acid, Ergocalciferol, Nicotinamide, Retinol, Riboflavi Review and Abidec(ascorbic Acid, Ergocalciferol, Nicotinamide, Retinol, Riboflavi Label ), SANDOZ (View Sandoz Review and Sandoz Label ), PHOSPHATE (POTASSIUM BICARBONATE, SODIUM BICARBONATE, SODIUM PHOSPHATE (View Phosphate (potassium Bicarbonate, Sodium Bicarbonate, Sodium Phosphate Review and Phosphate (potassium Bicarbonate, Sodium Bicarbonate, Sodium Phosphate Label ), CEFOTAXIME SODIUM (View Cefotaxime Sodium Review and Cefotaxime Sodium Label ).

5812307-1 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Dry Skin, Hepatic Enzyme Increased, Rash, Weight Increased
on Jun 30, 2008 Female patient from UNITED STATES , 54 years of age, weighting 153.0 lb, was diagnosed with psoriasis and was treated with Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, dry skin, hepatic enzyme increased, rash (What is rash?), weight increased. Taclonex dosage: Qd, Topical. During the same period patient was treated with DOVONEX (Qd, Topical) (View Dovonex Review and Dovonex Label ), SYNTHROID (LEVOTHYROXINE SODIUM), 50 MCG (View Synthroid (levothyroxine Sodium), 50 Mcg Review and Synthroid (levothyroxine Sodium), 50 Mcg Label ), MULTIVITAMIN /00831701/ (VITAMINS NOS) (View Multivitamin /00831701/ (vitamins Nos) Review and Multivitamin /00831701/ (vitamins Nos) Label ), CALCIUM (CALCIUM) (View Calcium (calcium) Review and Calcium (calcium) Label ), VITAMIN B6 (View Vitamin B6 Review and Vitamin B6 Label ).

5792657-8 | Condition Aggravated, Dermatitis Exfoliative, Discomfort, Inflammation, Malaise, Psoriasis
Patient was taking Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: condition aggravated, dermatitis exfoliative, discomfort, inflammation, malaise, psoriasis on Jun 12, 2008 from SPAIN Additional patient health information: Male patient , 48 years of age, was diagnosed with psoriasis and. Taclonex dosage: 80 Mg, Topical. During the same period patient was treated with HUMIRA (Subcutaneous) (View Humira Review and Humira Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), EPROSARTAN MESILATE (EPROSARTAN MESILATE) (View Eprosartan Mesilate (eprosartan Mesilate) Review and Eprosartan Mesilate (eprosartan Mesilate) Label ). Patient was hospitalized.

5776131-0 | Dermatitis Exfoliative
Adverse event was reported on Jun 02, 2008 by a Male patient taking Taclonex (View Usage) (Dosage: Topical) . Location: SPAIN , 48 years of age, Patient had the following side effects: dermatitis exfoliative. During the same period patient was treated with ADALIMUMAB(ADALIMUMAB) (View Adalimumab(adalimumab) Review and Adalimumab(adalimumab) Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), EPROSARTAN MESILATE(EPROSARTAN MESILATE) (View Eprosartan Mesilate(eprosartan Mesilate) Review and Eprosartan Mesilate(eprosartan Mesilate) Label ). Patient was hospitalized.

5765141-5 | Dermatitis Contact, Pustular Psoriasis
on May 21, 2008 Male patient from FRANCE , 59 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). After Taclonex was administered, patient had the following side effects: dermatitis contact, pustular psoriasis. Taclonex dosage: Topical. During the same period patient was treated with BISEPTINE /01186301/(BENZALKONIUM CHLORIDE, BENZYL ALCOHOL CHLORHEXIDI (View Biseptine /01186301/(benzalkonium Chloride, Benzyl Alcohol Chlorhexidi Review and Biseptine /01186301/(benzalkonium Chloride, Benzyl Alcohol Chlorhexidi Label ), EOSINE (EOSINE) (View Eosine (eosine) Review and Eosine (eosine) Label ). Patient was hospitalized.

5755903-2 | Erythrodermic Psoriasis
on May 15, 2008 Male patient from UNITED KINGDOM , 66 years of age, was diagnosed with psoriasis and was treated with Taclonex (View Usage). Patient experienced the following unwanted or unexpected effects: erythrodermic psoriasis. Taclonex dosage: 0.0005/064%, Qd, Topical. Patient was hospitalized.

5736232-X | Hyperglycaemia
Patient was taking Taclonex (View Usage). Patient had the following side effects: hyperglycaemia on Jan 29, 2008 from UNITED STATES Additional patient health information: Male patient , 67 years of age, weighting 160.1 lb, was diagnosed with psoriasis and. Taclonex dosage: Qd, Topical. During the same period patient was treated with LISINOPRIL (View Lisinopril Review and Lisinopril Label ), LIPITOR (ATOVRASTATIN CALCIUM) (View Lipitor (atovrastatin Calcium) Review and Lipitor (atovrastatin Calcium) Label ), BABY ASPIRIN (ACETYSALICYLIC ACID) (View Baby Aspirin (acetysalicylic Acid) Review and Baby Aspirin (acetysalicylic Acid) Label ), HUMALOG /00030501/ (INSULIN) (View Humalog /00030501/ (insulin) Review and Humalog /00030501/ (insulin) Label ), VITAMINS WITH MINERALS (View Vitamins With Minerals Review and Vitamins With Minerals Label ).